4D Pharma

4D Pharma is a world leader in the development of Live Biotherapeutics, an emerging class of drugs defined by the FDA as biological products containing live organisms, such as bacteria, that can be used to prevent or treat diseases. 4D Pharma has developed a proprietary platform that enables the rational identification of novel bacterial strains based on a deep understanding of their function and mechanism.4D Pharma's Live Biotherapeutic products are single bacterial strains delivered orally, which naturally exist in a healthy human gut. 4D Pharma is currently conducting four clinical studies: a Phase II study of Blautix for irritable bowel syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in the neoadjuvant setting for patients with solid tumors, and a Phase I/II study of MRx-4DP0004 in asthma. Other key programs focus on disease areas such as central nervous system disorders.